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Four prostaglandin (PG)E2 receptors have been described, termed E-series prostaglandin receptors (EP1–EP4), that
can be further subclassiﬁed as low-afﬁnity (EP1 and EP2) or high-afﬁnity (EP3 and EP4) receptors. Activation of the
low-afﬁnity PGE2 receptors is likely to be important in mediating the actions of the high levels of PGE2 found in
various pathologic processes. The pattern of expression of these receptors in epidermis, however, is unknown. We
therefore examined the immunolocalization of the EP1 and EP2 receptors in human epidermis. The EP1 and EP2
receptors demonstrated both plasma membrane and perinuclear or nuclear staining within the basal and spinous
layers. Within the granular layer, both receptors were expressed in the cytoplasm with a grainy or granular ap-
pearance. The major differences were that the EP2 receptor demonstrated a zone of decreased to absent plasma
membrane staining in the superﬁcial spinous layer and only scattered cellular staining within the granular layer. In
contrast, the EP1 receptor was prominently expressed throughout the stratum granulosum and the plasma mem-
brane staining pattern was seen throughout the spinous layer. In cultured primary human keratinocytes, we also
veriﬁed the presence of functional EP1 receptor coupled to intracellular calcium mobilization and EP2 receptor
coupled to cAMP production.
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Prostaglandin E2 (PGE2) has an important role in regulating
keratinocyte growth, differentiation, and apoptosis (Lo et al,
1998; Goldyne, 2000). PGE2 is formed by cleavage of
arachidonic acid from cellular phospholipids, followed by its
conversion to PGH2 by one of two cyclooxygenases (COX-1
and -2). Increased COX-2 activity and expression has been
shown to mediate pathologic skin changes associated with
wound repair, inflammatory diseases, ultraviolet irradiation,
and neoplasia (Goldyne, 2000; Iversen and Kragballe, 2000;
Lee et al, 2003). The presence of both COX-1 and COX-2
has been demonstrated in both normal and neoplastic hu-
man skin (Goldyne, 2000).
PGE2 acts by binding to one of four different het-
erotrimeric G-protein coupled receptors (GPCR), termed E-
series prostaglandin receptors (EP1–EP4) (Breyer et al,
2001). These receptors differ in the second messenger
pathways activated upon PGE2 binding. The receptors can
be roughly broken into two receptor classes based on their
PGE2-binding affinities. High-affinity receptors, EP3 and
EP4, bind PGE2 at subnanomolar levels, whereas low-affin-
ity EP1 and EP2 receptors have dissociation constants in the
low nanomolar range. EP2 and EP4 receptors are coupled to
adenylate cyclase activation, whereas EP1 receptors are
coupled to cytosolic and nuclear calcium mobilization and
activation of phospholipase C. EP3 receptors have multiple
splice variants that have been shown to signal through Gai,
Gas, Ga13, and Gbg subunits (Hatae et al, 2002).
The presence of multiple receptor subtypes with different
PGE2-binding affinities and signaling pathways demon-
strate the diversity of PGE2-mediated signaling. The ability
to mechanistically define the role of PGE2 in epidermal
physiology and pathology is therefore dependent on first
establishing the expression and function of the individual
PGE2 receptors in skin. We have previously demonstrated
that primary human keratinocytes (PHK) in culture express
transcripts for EP24 receptors and that the low-affinity EP2
receptor stimulates growth in non-confluent PHK in vitro
(Konger et al, 1998).
Compared with high-affinity receptors that would be ex-
pected to be fully activated at low levels of PGE2 produc-
tion, the low-affinity PGE2 receptors are likely to be of
relatively greater importance under pathologic conditions
associated with increased PGE2 production. Thus, in order
to better understand how PGE2 functions in human skin, we
examined the expression and localization of both low-af-
finity EP receptor subtypes in normal adult human skin. To
verify that these receptors are expressed and functionally
active in keratinoctyes, we also examined their expression
Abbreviations: COX, cyclooxygenase; EP, E-series prostaglandin
receptor; GPCR, G-protein coupled receptor; HEK, human em-
bryonic kidney; HIER, heat-induced epitope retrieval; IHC,
immunohistochemistry; PBS, phosphate-buffered saline; PGE2,
prostaglandin E2; PHK, primary human keratinocyte
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in cultured PHK and demonstrated functional coupling to
downstream second messengers.
Results and Discussion
Primary antibody speciﬁcity Prior to performing im-
munohistochemistry (IHC) or immunoblots, we first exam-
ined the specificity of the polyclonal anti-EP1 and anti-EP2
receptor antibodies by western blot. The EP1 receptor
immunoblot demonstrated two major bands centered at
approximately 40 and 61 kDa in human embryonic kidney
(HEK) cells overexpressing the EP1 receptor (see arrows in
Fig 1a). These bands were not present in control membrane
preparations, or membrane preparations from cells overex-
pressing the EP2. The 61 kDa band is similar in size to the
rat EP1 receptor reported by others (Southall and Vasko,
2001). The 40 kDa band corresponds well with the predict-
ed molecular weight for the human EP1 receptor based on
its amino acid sequence (41,858 Da) (Funk et al, 1993). Ad-
ditional less intense bands are observed just below and
above the 40 and 61 kDa bands. These bands are not seen
in control cells. The presence of multiple bands by western
blot is often observed with GPCR (Stillman et al, 1999; Boer
et al, 2000; Konger et al, 2002; Salahpour et al, 2003). Pre-
sumably, this occurs because of differences in receptor
glycosylation and the propensity of the highly hydrophobic
heptahelical GPCR to form SDS-insoluble homo and he-
tero-complexes. As two major bands were observed, we
verified that bands of the same molecular weight are de-
tected by immunoblot using a second monoclonal antibody
(clone 5F12) produced in this laboratory (Fig S1).
The specificity of the EP2 receptor polyclonal antibody is
seen in the immunoblot in Fig 1b. In HEK cells overex-
pressing the EP2 receptor, a broad band centered at ap-
proximately 55 kDa was the dominant immunoreactive
protein. Three additional less intense lower molecular
weight bands were also observed at approximately 38,
40, and 45 kDa.
Immunohistochemical localization of the EP1 and EP2
receptor in normal human epidermis As EP1 receptor
expression has not been characterized in normal intact ep-
idermis, we examined EP1 receptor localization by IHC
(Fig 2). Figure 2a shows a low power photomicrograph of EP1
immunolocalization in normal epidermis. The most promi-
nent feature is the presence of pronounced cytoplasmic
staining of cells within the granular layer (see arrow in Fig
2a). In Fig 2b, an area of less intense granular layer staining
is shown to better illustrate the course granular cytoplasmic
staining pattern within individual cells (see arrow). In addi-
tion, both plasma membrane and perinuclear/nuclear re-
ceptor localization is observed in the basal layer and
stratum spinosum (see Fig 2a–c). The high-power image in
Fig 2c demonstrates the pronounced plasma membrane
staining pattern in the basal and spinous layers (large
arrow). In addition, nuclear and perinuclear staining (small
arrows) is observed in scattered cells throughout the basal
and spinous layers.
Figure 2d demonstrates the absence of significant
staining following pre-absorption with immunogenic-free
peptide. In addition, no staining was observed following
substitution of the primary antibody with equal concentra-
tions of irrelevant rabbit IgG (data not shown).
As further evidence that the staining pattern observed
was specific, we also performed IHC staining using a
monoclonal antibody (clone 5F12) produced in this labora-
tory (data not shown). The overall pattern was essentially
identical to that seen with the polyclonal antibody prepa-
ration.
Similar to the EP1 receptor, EP2 receptor localization has
not been described in normal human epidermis. We there-
fore examined EP2 receptor expression by IHC using po-
lyclonal rabbit anti-EP2 receptor antibodies. As with the EP1
receptor, both perinuclear/nuclear staining and outer mem-
brane staining pattern was observed in the basal and spin-
ous layers (see low power and medium power images in
Fig 3a and b). The large arrows in Fig 3b and c point out
areas of plasma membrane staining. In contrast to the EP1
receptor, however, a marked decrease in the membrane
staining pattern was observed in the superficial stratum
spinosum. This is seen in both the low- and medium- power
photomicrographs (Fig 3a and b). In addition, a granular-
appearing cytoplasmic staining pattern was seen in the
stratum granulosum (long arrow in Fig 3b). But, this staining
was less intense and involved only scattered cells. In the
high-power image seen in Fig 3c, the outer membrane
staining pattern (large arrow) and the perinuclear/nuclear
staining (small arrows) are illustrated. In Fig 3d, pre-absorp-
tion with the immunogenic-free peptide resulted in the ab-
sence of significant staining.
As heptahelical transmembrane receptors, the observed
localization of the PGE2 receptors to the plasma membrane
was expected. But, GPCR can also be localized to in-
tracellular membranes, including that of the nucleus,
endoplasmic reticulum, golgi apparatus, and endosomal
bodies. Moreover, nuclear membrane localization has been
Figure 1
Specificity of the polyclonal anti-human E-series prostaglandin
receptors (EP1 and EP2) antibodies. (a) Sixty micrograms per lane of
membrane preparations from control HEK-293 (human embryonic kid-
ney (HEK)) cells or HEK-293 cells overexpressing the human EP1
(pEP1–HEK) and EP2 (pEP2–HEK) receptors were electrophoresed on
12% SDS-PAGE gels and transferred to PVDF membranes. Immuno-
blotting was carried out with a polyclonal anti-EP1 receptor antibody.
After stripping the membrane, immunoblotting was then carried out for
a-tubulin expression. (b) Specificity of the polyclonal anti-human EP2
receptor antibody for the EP2 receptor. Immunoblot was carried out as
described above for the EP1 receptor.
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demonstrated for the EP1, EP3, and EP4 receptors in other
cell types or tissues (Bhattacharya et al, 1998, 1999;
Schlotzer-Schrehardt et al, 2002). Thus, it is interesting that
both plasma membrane and nuclear or perinuclear staining
were observed for the EP1 and EP2 receptor in human skin.
This subcellular pattern of staining is consistent with radio-
ligand binding data using crude rat skin subcellular mem-
brane preparations (Lord et al, 1978).
The localization of low-affinity receptors in a perinuclear/
nuclear pattern is interesting, given that COX-1 and COX-2
are known to be localized to the endoplasmic reticulum and
nuclear membrane (Otto and Smith, 1994; Morita et al,
1995). This suggests that the low-affinity PGE2 receptors
are responsive to PGE2 production at the nuclear envelope
or endoplasmic reticulum and are possibly involved in nu-
clear second messenger signaling. In support of this idea,
the EP1 receptor is known to be coupled to nuclear calcium
signaling in other cell types (Bhattacharya et al, 1998;
Breyer et al, 2001).
Finally, the cytoplasmic staining pattern within the gran-
ular layer suggests that receptor localization shifts to intra-
cellular organelles or endosomal structures such as lamellar
Figure 2
Immunohistochemical localization of the
E-series prostaglandin receptor (EP1)
in human epidermis. (a) Low-power pho-
tomicrograph showing prominent granular
layer staining of the epidermis (arrow). Both
plasma membrane and perinuclear/nuclear
localization are also apparent. (b) Medium-
power photomicrograph demonstrating the
grainy or granular-appearing cytoplasmic
staining of cells within the stratum granulo-
sum (arrow). (c) High-power photomicro-
graph showing distinct plasma membrane
staining (large arrows) and perinuclear/nu-
clear staining (small arrows). (d) Medium-
power photomicrograph showing the
absence of appreciable staining after pre-
absorption of the primary antibody with
immunogenic free peptide. Photomicro-
graphs are representative of immunohisto-
chemical staining carried out on five
different individuals. 3-amino, 9-ethyl-car-
bazole (AEC) substrate was used for all
images. Scale bar¼ 50 mm.
Figure 3
Immunohistochemical localization of
the E-series prostaglandin receptor
(EP2) in human epidermis. (a) Low-pow-
er photomicrograph showing prominent
membrane staining in the basal and
lower spinous layers. Perinuclear/nuclear
staining is seen throughout the basal and
spinous layers. Scattered cells within the
stratum granulosum demonstrate posi-
tive cytoplasmic staining. (b) Medium-
power photomicrograph demonstrating
the grainy or granular-appearing cytoplas-
mic staining of cells within the stratum
granulosum (long arrow). Clearing of the
plasma membrane staining is observed as
well in the upper spinous layer. (c) High-
power photomicrograph showing plasma
membrane staining (large arrows) and peri-
nuclear/nuclear staining (small arrows). (d)
Medium-power photomicrograph showing
the absence of appreciable staining after
pre-absorption of the primary antibody
with immunogenic-free peptide. Photomi-
crographs are representative of immuno-
histochemical staining carried out on six
different individuals. Diaminobenzidine tet-
rahydrochloride (DAB) substrate was used
in all images. Scale bar¼ 50 mm.
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bodies. The functional significance of this cytoplasmic
staining pattern in the stratum granulosum is, however,
unclear.
The EP1 receptor is expressed in PHK in culture and is
coupled to intracellular calcium-mobilization We next
demonstrated that the EP1 receptor is expressed in cultured
PHK by immunoblot (Fig 4a). PHK demonstrated two bands
comigrating with the 40 and 60 kDa bands seen in positive
control membrane preparations. We also verified that PHK
express the EP1 receptor mRNA by RT-PCR and northern
analysis (data not shown).
In Fig 4b, we demonstrate that 1.6 mM of the EP1/EP3
agonist sulprostone induces a rapid and transient cytoplas-
mic calcium mobilization. Similar results were seen on two
separate occasions. Only a slight rise in cytosolic calcium
was noted using 400 nM sulprostone (data not shown). The
binding affinities of sulprostone for the EP1 and EP3 recep-
tor are 107 and 0.35 nM, respectively (Abramovitz et al,
2000). Thus, the failure to observe a significant calcium rise
at concentrations less than 400 nM strongly argues against
EP3 receptor involvement. Ethanol alone had no affect on
calcium mobilization (see Fig S2). The platelet-activating
factor receptor agonist, carbamyl-PAF, was used as a pos-
itive control (Travers et al, 1995). Carbamyl-PAF (16 mg per
mL) resulted in a similar rise in intracellular calcium (Fig S2).
Calcium mobilization is essential for keratinocyte differ-
entiation (Hennings et al, 1980; Evans et al, 1993). Thus, one
potential role for the EP1 receptor would be in regulating
keratinocyte differentiation. This is consistent with the
prominent granular layer staining for the EP1 receptor as
well as staining within the spinous layer (Fig 2). But, ex-
pression within the basal layer might be indicative of a pos-
itive or negative role in keratinocyte growth. Interestingly,
the EP1 receptor is reported to stimulate the growth of ma-
lignant murine keratinocytes (Thompson et al, 2001).
The EP2 receptor is expressed in PHK and is coupled to
adenylate cyclase activation In Fig 5a, we demonstrate
that PHK express a 55 kDa band by immunoblot that cor-
responds to the major band observed in the EP2 overex-
pressing HEK-293 cells. In Fig 5b, we show that the highly
specific EP2 agonist, CAY10399, induces a significant ele-
vation of cAMP. CAY10399 has a Ki of binding to the EP2
receptor of 92 nM, with negligible binding to other receptor
subtypes (Tani et al, 2001). These results are in agreement
with our earlier report showing that EP2 receptors are cou-
pled to cAMP production (Konger et al, 1998). In this pre-
vious report, we also demonstrated that EP2 receptor
activation results in keratinocyte proliferation. Thus, the in-
creased plasma membrane and perinuclear/nuclear stain-
ing observed in the basal layer and lower spinous layer
would be consistent with a role in cell proliferation. In ad-
dition, expression of the EP2 receptor within the spinous
and granular layer might indicate an additional positive or
negative role in keratinocyte differentiation.
In summary, we demonstrate that both low-affinity PGE2
receptors are expressed in normal skin and in PHK in cul-
ture. As expected, the EP2 receptor is coupled to cAMP
production whereas the EP1 receptor is coupled to intra-
cellular calcium mobilization. Differences in receptor local-
ization within the stratified epidermis suggest that the two
receptors may have different primary functions within the
epidermis. Finally, both receptors demonstrated a plasma
membrane, nuclear and/or perinuclear, and cytoplasmic
pattern of staining. How this change in subcellular localiza-
tion alters the functional activity of the receptors is unclear,
but it does serve to add another layer of complexity in at-
tempting to understand the receptor-based mechanisms by
which PGE2 exerts its influence on cutaneous biology.
Methods
Skin procurement and isolation and culture of PHK Adult PHK
were prepared from the epidermis obtained from discarded reduc-
tive mammoplasties and panniculectomies as previously described
(Konger et al, 1998). For immunohistochemical studies, intact skin
was cut into small sections, fixed in 10% buffered formalin for 3–4 h,
and paraffin-embedded. All use of human skin was conducted
Figure 4
Primary human keratinocytes (PHK) express functional E-series
prostaglandin receptor (EP1) coupled to intracellular calcium mo-
bilization. (a) Immunoblot showing EP1 receptor expression (arrows) in
PHK total cell lysates (50 mg) compared with 10 mg per lane of mem-
brane preparations from human embryonic kidney (HEK)-293 cells ex-
pressing either empty vector control (HEK) or overexpressing the
human EP1 receptor (pEP1–HEK). (b) Intracellular calcium mobilization
is shown in Fura PE3/AM-loaded PHK treated with 1.6 mM of the EP1/
EP3 receptor agonist sulprostone.
Figure5
Primary keratinocytes express functional E-series prostaglandin
receptor (EP2) coupled to adenylate cyclase activation. (a) Immuno-
blot showing EP2 receptor expression (arrow) in primary human ker-
atinocytes (PHK) total cell lysates (75 mg) compared with 10 mg per lane
of membrane preparations from human embryonic kidney (HEK)-293
cells expressing either empty vector control (HEK) or overexpressing
the human EP2 receptor (pEP2–HEK). (b) Cyclic AMP induction ob-
served in PHK following stimulation with vehicle control or 10 nM of the
highly specific EP2 receptor agonist, CAY10399.
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according to the Declaration of Helsinki principles and was ap-
proved by the Institutional Review Boards of both Indiana Univer-
sity in Indianapolis and the University of Rochester.
IHC After deparaffinization and rehydration, slides were immersed
in either a high pH heat-induced epitope retrieval (HIER) solution
(Dakocytomation, Carpinteria, California) diluted with 90% glycerol
(EP1 receptor) or 75% glycerol (EP2 receptor) followed by auto-
claving for 20 min at 1201C. After cooling for 20 min, the slides
were permeabilized in phosphate-buffered saline (PBS) containing
0.25% Triton X-100 and treated with PeroxoBlock (Zymed Labo-
ratories, South San Francisco, California). After washing, primary
antibody diluted to 5–10 mg per mL in PBS containing 0.1% bovine
serum albumin and 10% CAS block (Zymed Laboratories) was
added for 1 h (EP2) or 2
1/2 h (EP1) at room temperature. The
remainder of the staining protocol was conducted using the Pic-
Ture Plus broad-spectrum IHC staining kit (Zymed Laboratories,
South San Francisco, California) as per the manufacturer’s in-
structions utilizing either 3-amino, 9-ethyl-carbazole (AEC) or di-
aminobenzidine tetrahydrochloride (DAB) as substrates (Zymed
Laboratories).
Preparation of total cell lysates from PHK cultures PHK were
grown in six-well plates to approximately a 50%–60% confluent
monolayer in Keratinocyte-SFM (K-SFM) containing 0.06 mM cal-
cium (EP2 immunoblot) or in DMEM containing 10% fetal bovine
serum (EP1 immunoblot). Monolayers were then washed with PBS
and lysed for two hours at 41C in 0.35 mL RIPA buffer containing a
1:100 dilution of a protease inhibitor cocktail (Sigma-Aldrich, St
Louis, Missouri). After a brief sonication, the preparation was cen-
trifuged at 16,000  g for 15 min. One volume of denaturation
buffer (10 M urea, 4% SDS, 200 mM DTT) was then added to the
cleared supernatants. After incubating overnight at 41C, 4  La-
emmli’s buffer was added prior to loading on a 12% SDS-PAGE
gel.
HEK-293 membrane preparation Isolated membrane prepara-
tions from HEK cells (HEK-293) stably expressing the human EP1
and EP2 receptors were generous gifts from Dr Kathleen Metters,
(Merck-Frosst Centre for Therapeutic Research; Quebec, Canada)
(Funk et al, 1993). The membrane preparations were solubilized in
2  Laemmli’s buffer (Konger et al, 2002). Protein preparations
were either kept on ice for the EP1 receptor, or for EP2 receptor
western blot, boiled for 5 min to heat denature the membrane
preparations.
Western blot analysis for EP1 and EP2 receptor After separation
on 12% SDS-PAGE gels, proteins were transferred to either PVDF
or nitrocellulose membranes for immunoblot. Membranes were
blocked overnight at 41C with 5% Blotto in tris-buffered saline, pH
8.0 (TBS). Primary antibodies (polyclonal anti-EP1 and anti-EP2
antibodies: Cayman Chemical, Ann Arbor, Michigan) were pre-
pared as a 1:1000 dilution in TBS containing 1% blotto and incu-
bated for 1.5 h at room temperature. Immunoreactive bands
were detected by enhanced chemiluminescence following a 1.5 h
incubation with goat anti-rabbit horseradish peroxidase (Dakocyto-
mation) secondary antibody-diluted 1:2000 in TBSTwith 1% blotto.
Intracellular Ca2þmeasurements PHK were grown in serum-free
media containing 0.06 mM calcium, bovine pituitary extract, and
epidermal growth factor (K-SFM, Invitrogen, Carlsbad, California).
Prior to Fura PE3/AM loading, confluent monolayers were pre-
treated for 48 h with indomethacin (3 mg per mL) to block endog-
enous PGE2 production. Cells were then loaded with 5 mM Fura
PE3/AM-ester (Fisher Scientific, Hanover Park, Illinois) in growth
supplement-free K-SFM containing 3 mg per mL indomethacin for
1 h at 371C. After loading, the monolayer was washed 2 times with
Hank’s balanced salt solution (HBSS) containing 1.26 mM calcium
(Sigma, St. Louis, Missouri). The cells were then detached by try-
psinization, centrifuged, and resuspended in HBSS. Resuspended
cells were incubated at room temperature for 30 min. For intracel-
lular Ca2þ measurements, 2.5 mL of cells in HBSS were loaded
into a standard cuvette containing a magnetic stirring device. The
cuvette was placed into a thermostatically controlled magnetic
stirring chamber at 371C in a Hitachi F-2000 fluorescence spec-
trophotometer. After establishing a baseline calcium level, 20 mL of
0.2 mM sulprostone, diluted in ethanol (final concentration¼
1.6 mM), was injected into the cuvette using an injection port. Ex-
citation wavelengths were 340 nm and 380 nm, and emitted light
measured at 510 nm. Ratiometric recordings were produced using
F-2000 software (Hitachi Instruments, Naperville, Illinois). As a ve-
hicle control, 20 mL of ethanol was added. For a positive control,
carbamyl-PAF (16 mg per mL) was added.
EP2-agonist (CAY10399) induced cAMP production Measure-
ment of cAMP production was performed as previously described
using 10 nM of the highly specific EP2 receptor agonist (CAY10399)
(Konger et al, 2002).
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